NCT06723015
Tau PET Outcomes With Anti-amyloid Immunotherapies
Enrolling by Invitation
PHASE2Ages 50–90InterventionalMayo ClinicInvestigator-initiated
~135 participants
Updated 2025-11-18 on ClinicalTrials.gov
What's tested:18F-AV-1451
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in tau PET Standardized Uptake Value (SUVR)
Measured over Baseline, 18 months
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Petrice Cogswell, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age 50-90 years
Male or female
Mild cognitive impairment due to AD or mild AD
Amyloid positive via CSF or PET
Meets other eligibility criteria for anti-amyloid immunotherapy
Subject or delegate provides informed consent
Exclusion
Subjects unable to lie down without moving for 10 minutes.
Women who are pregnant or cannot stop breast feeding for 24 hours.
Claustrophobic patients unable to tolerate the scans (no sedation can be offered).
What this trial measures
- Change in tau PET Standardized Uptake Value (SUVR)Baseline, 18 months
A PET Standardized Uptake Value (SUV) is measured by calculating the ratio of the radioactivity concentration within a specific region of interest (ROI) on a PET scan, divided by the injected dose of the radiotracer per unit of the patient's body weight. The calculated Standardized Uptake Value (SUVR) is reported as a single number, with higher values indicating greater tracer uptake in the target region relative to the reference region